Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in ...

The SPLASH Phase 3 trial showed significant improvement in radiographic progression-free survival with 177Lu-PNT2002 in mCRPC patients, with a 38.1% overall response rate vs. 12.0% for ARPI. Patients also demonstrated improved health-related quality of life and statistically significant overall survival benefits. The study met its primary endpoint, with a median rPFS of 9.5 months for 177Lu-PNT2002 vs. 6.0 months for ARPI.